Bio-Techne Corp (TECH)

Net profit margin

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Net income (ttm) US$ in thousands 73,400 131,666 158,137 150,712 168,105 203,001 224,160 246,700 285,262 271,302 261,823 291,991 272,051 225,487 210,530 176,631 140,411 184,298 174,948 248,296
Revenue (ttm) US$ in thousands 1,219,634 1,208,768 1,196,015 1,171,582 1,159,059 1,154,281 1,144,999 1,143,982 1,136,702 1,123,611 1,119,841 1,117,536 1,105,600 1,076,399 1,029,575 984,552 931,032 847,838 798,966 759,647
Net profit margin 6.02% 10.89% 13.22% 12.86% 14.50% 17.59% 19.58% 21.57% 25.10% 24.15% 23.38% 26.13% 24.61% 20.95% 20.45% 17.94% 15.08% 21.74% 21.90% 32.69%

June 30, 2025 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $73,400K ÷ $1,219,634K
= 6.02%

The net profit margin of Bio-Techne Corp has exhibited notable fluctuations over the analyzed period. Starting at a high of 32.69% as of September 30, 2020, the margin experienced a significant decline through subsequent periods, reaching a low of approximately 6.02% projected for June 30, 2025. In particular, the trend demonstrates considerable volatility, with periods of modest recovery, such as the increases observed in the quarters ending June 30, 2022 (24.61%) and September 30, 2022 (26.13%), and slight improvements in late 2023 reaching approximately 19.58%.

However, from this peak, the margin has generally been declining, reflecting a downward trend in profitability relative to revenues. The decrease becomes more pronounced starting in the second half of 2024, with projections indicating a continued decline through mid-2025. This pattern suggests that the company's profitability, measured by net profit as a percentage of revenue, has been under pressure in recent periods and is expected to diminish further in the near term.

Overall, the trajectory of Bio-Techne Corp's net profit margin indicates a contraction in profit efficiency over time, highlighting potential challenges in maintaining previous levels of profitability amid evolving market conditions or internal operational factors.